Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

A Potential Psychedelic and COVID Therapy Play…All in One Stock

Dave Jackson Dave Jackson, Stockhouse
1 Comment| June 18, 2020

{{labelSign}}  Favorites
{{errorMessage}}

The global concern over the ongoing coronavirus pandemic isn’t going away and even the White House’s health advisor is concerned about what protection a potential vaccine may deliver…but…could there be an answer in a drug that already exists?

With a focus on the R&D of therapeutics for infectious diseases and rare disorders, specialty life sciences Company Revive Therapeutics Ltd. (CSE: RVV, OTC: RVVTF, Forum) is advancing development on what could potentially be a major windfall as the world continues to grapple with the COVID-19 coronavirus pandemic.

The Company is taking advantage of several F-D-A incentives to explore the use of Bucillaminefor the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19. Revive Therapeutics also just made news when it filed its Clinical Trial Application with Health Canada.

Stockhouse Editorial’s Dave Jackson was joined by Revive Therapeutics CEO Michael Frank and Derrick Welsh, Founder and C-O-O of Psilocin Pharma Corp, to talk more about what amazing possibilities Bucillamine could offer, future investment opportunities in the exploding magic / mushroom / psilocybin space, and to learn more about their companies in general.




Download the episode here.

Listen on Apple PodcastsListen on Google Podcasts



FULL DISCLOSURE: This is a paid article of Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

Great time to get in early!
(205)
October 24, 2020

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today